The Cancer Radiation Therapy Market remains a cornerstone in oncology, with over 60% of all cancer patients receiving radiation at some point. From localized external beams to internal brachytherapy, these treatments are becoming more precise, safe, and efficient.

Market Forecast

Projected to reach USD 136.16 billion by 2031, the market is fueled by the global rise in cancer prevalence, technological breakthroughs in radiotherapy systems, and the adoption of AI in treatment planning.

Technology Spectrum

• External Beam Radiation Therapy (EBRT): Most widely used and includes IMRT, 3D-CRT, and proton therapy.

• Internal Therapy (Brachytherapy): Especially used in prostate, cervical, and breast cancers.

• Systemic Radiation: Radioactive drugs for targeted internal radiation.

Application Areas

• Breast, lung, prostate, colorectal, and head & neck cancers.

• Used in curative, adjuvant, and palliative care.

Innovations

• AI and machine learning in treatment simulation.

• Personalized dose planning based on tumor genetics.

• Mobile radiation therapy units in underserved regions.

Global Landscape

• North America: Early adopter with comprehensive oncology centers.

• Asia-Pacific: Highest CAGR, with growing hospital investments and increasing public health initiatives.

• Europe: Balanced adoption with ongoing innovation in radiotherapy-drug combinations.